Farglitazar

From WikiMD.org
Jump to navigation Jump to search

Farglitazar

Farglitazar (pronounced: far-gli-ta-zar) is a Peroxisome proliferator-activated receptor (PPAR) modulator that was under development for the treatment of Type 2 diabetes. It is a member of the Thiazolidinedione class of drugs, which are known for their insulin-sensitizing effects.

Etymology

The name "Farglitazar" is derived from the class of drugs it belongs to, the Thiazolidinediones, and its unique chemical structure. The "far" prefix is an abbreviation of "farnesoid X receptor", one of the receptors it was designed to target. The "glitazar" suffix is common among PPAR modulators, indicating its function and class.

Mechanism of Action

Farglitazar works by activating the Peroxisome proliferator-activated receptor gamma (PPARγ), a key regulator of glucose and lipid metabolism in the body. By activating PPARγ, Farglitazar enhances insulin sensitivity, leading to improved blood glucose control.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski